Filter Results:
(793)
Show Results For
- All HBS Web
(1,552)
- People (1)
- News (333)
- Research (793)
- Multimedia (8)
- Faculty Publications (574)
Show Results For
- All HBS Web
(1,552)
- People (1)
- News (333)
- Research (793)
- Multimedia (8)
- Faculty Publications (574)
Sort by
- 04 May 2010
- First Look
First Look: May 4
including commercial banks, investment banks, hedge funds, and private equity funds. Representing one of the largest DIP loans in history, this financing was considered critical to the company's survival. One unique and controversial... View Details
Keywords: Martha Lagace
- June 2012 (Revised October 2018)
- Case
Home Nursing of North Carolina
By: Richard S. Ruback and Royce Yudkoff
Ari Medoff's (HBS '11) goal was to control his own professional destiny by owning his own company. His search identified a suitable acquisition in Home Nursing of North Carolina, and he had negotiated a purchase price of $3.5 million, or 4.2x trailing EBITDA. Medoff... View Details
Keywords: Search Funds; Small Companies; Acquisitions; Negotiation; Medical Services; Negotiation Process; Valuation; Investment; Acquisition; Health Industry
Ruback, Richard S., and Royce Yudkoff. "Home Nursing of North Carolina." Harvard Business School Case 212-120, June 2012. (Revised October 2018.)
- February 2002 (Revised May 2004)
- Case
U.S. Labs
By: Michael J. Roberts and Robert F. Higgins
Describes the evolution of a start-up venture in the pathology lab segment of the clinical lab business. U.S. Labs tries a series of business models before running out of cash. The company is in dire need of financing, as its venture capital backers are refusing to put... View Details
Keywords: Entrepreneurship; Business Startups; Venture Capital; Financial Strategy; Financing and Loans; Business Model; Business or Company Management; Planning; Business Strategy; Health Industry
Roberts, Michael J., and Robert F. Higgins. "U.S. Labs." Harvard Business School Case 802-163, February 2002. (Revised May 2004.)
- 22 Apr 2002
- Research & Ideas
Profits and Prophets: The Role of Values in Investment
provided a good return for a pension fund holder at some point, but that investor and society pay more in the end through increased health care costs. Hayes said that Domini's picture of a system run amok, with perhaps the need for a... View Details
Keywords: by Sean Silverthorne
- March 2010 (Revised June 2010)
- Case
Whose Money Is It Anyway? (A)
By: V.G. Narayanan, Richard G. Hamermesh and Rachel Gordon
The Brigham and Women's Physician's Organization (BWPO) and its corporate parent disagree over who has jurisdiction over significant legacy funds. Are they controlled by the BWPO or do they belong to BWPO's corporate parent? The BWPO and its corporate parent must... View Details
Keywords: Accounting; Investment Funds; Governance Controls; Agreements and Arrangements; Boundaries; Health Industry
Narayanan, V.G., Richard G. Hamermesh, and Rachel Gordon. "Whose Money Is It Anyway? (A)." Harvard Business School Case 810-008, March 2010. (Revised June 2010.)
- 04 Apr 2017
- First Look
First Look at New Research, April 4
https://cb.hbsp.harvard.edu/cbmp/product/817081-PDF-ENG Harvard Business School Case 516-051 Unigrains Unigrains is a French agribusiness-focused private equity firm that has provided specialized financing to France's agribusiness sector... View Details
Keywords: Sean Silverthorne
- June 2024
- Case
Alignvest Student Housing: Keep Building or Time to Sell?
By: Shikhar Ghosh and Patrick Sanguineti
Sanjil Shah, Managing Partner of Alignvest Student Housing REIT (ASH), faces the most significant decision thus far in his career: is it the right time to sell the company? Together with his partner Reza Satchu, Shah had developed ASH into the largest student housing... View Details
Keywords: Entrepreneur; Exit Strategy; Real Estate; Founder; Equity Valuation; Decisions; Entrepreneurial Finance; Interest Rates; Health Pandemics; Housing; Partners and Partnerships; Expansion; Canada
Ghosh, Shikhar, and Patrick Sanguineti. "Alignvest Student Housing: Keep Building or Time to Sell?" Harvard Business School Case 824-208, June 2024.
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details
Keywords: Nonprofit Organizations; Health Disorders; Health Care and Treatment; Resource Allocation; Global Range; Decisions; Investment Funds
Rangan, V. Kasturi, and Courtney Han. "The END Fund: To Eliminate Neglected Tropical Diseases." Harvard Business School Case 523-063, January 2023.
- 16 Oct 2013
- Op-Ed
Response to Readers: Combating Climate Change with Nuclear Power and Fracking
With more than 7,500 views and 180-plus tweets, I want to thank everyone for taking the time to read the original HBS Working Knowledge piece, The Case for Combating Climate Change with Nuclear Power and Fracking, and, in particular, for sharing your thoughts with one... View Details
- July–August 2018
- Article
Using Time-Driven Activity-Based Costing to Model the Costs of Various Process-Improvement Strategies in Acute Pain Management
By: Keyuri Popat, Kelly Ann Gracia, Alexis B. Guzman and Thomas W. Feeley
Pain control for patients undergoing thoracic surgery is essential for their comfort and for improving their ability to function after surgery, but it can significantly increase costs. Here, we demonstrate how time-driven activity-based costing (TDABC) can be used to... View Details
Keywords: Time-Driven Activity-Based Costing; Health Care and Treatment; Cost Management; Performance Improvement
Popat, Keyuri, Kelly Ann Gracia, Alexis B. Guzman, and Thomas W. Feeley. "Using Time-Driven Activity-Based Costing to Model the Costs of Various Process-Improvement Strategies in Acute Pain Management." Journal of Healthcare Management 63, no. 4 (July–August 2018): e76–e85.
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- Fall 2020
- Article
Business Credit Programs in the Pandemic Era
By: Samuel G. Hanson, Jeremy C. Stein, Adi Sunderam and Eric Zwick
We develop a pair of models that speak to the goals and design of the sort of business-lending and corporate-bond purchase programs that have been introduced by governments in response to the ongoing COVID-19 pandemic. An overarching theme is that, in contrast to the... View Details
Keywords: COVID-19; Business Lending; Government Intervention; Econometric Models; Health Pandemics; Credit; Governance; Policy
Hanson, Samuel G., Jeremy C. Stein, Adi Sunderam, and Eric Zwick. "Business Credit Programs in the Pandemic Era." Brookings Papers on Economic Activity (Fall 2020).
- Summer 2019
- Article
The Price Effects of Cross-Market Mergers: Theory and Evidence from the Hospital Industry
By: Leemore S. Dafny, Katherine Ho and Robin S. Lee
We consider the effect of mergers between firms whose products are not viewed as direct substitutes for the same good or service but are bundled by a common intermediary. Focusing on hospital mergers across distinct geographic markets, we show that such combinations... View Details
Keywords: Mergers and Acquisitions; Markets; Geographic Scope; Price; Outcome or Result; Insurance; Health Industry
Dafny, Leemore S., Katherine Ho, and Robin S. Lee. "The Price Effects of Cross-Market Mergers: Theory and Evidence from the Hospital Industry." RAND Journal of Economics 50, no. 2 (Summer 2019): 286–325.
- Article
Financial Incentive Based Approaches for Weight Loss: A Randomized Trial
By: Kevin Volpp, Leslie K. John, Andrea Troxel, Laurie Norton, Jennifer Fassbender and George Loewenstein
Volpp, Kevin, Leslie K. John, Andrea Troxel, Laurie Norton, Jennifer Fassbender, and George Loewenstein. "Financial Incentive Based Approaches for Weight Loss: A Randomized Trial." JAMA, the Journal of the American Medical Association 300, no. 22 (December 10, 2008): 2631–2637.
- Article
Unhealthy Consumerism: The Challenge of Trading Off Price and Quality in Healthcare
By: Kate Barasz and Peter A. Ubel
Over the last decade, healthcare in many parts of the world has shifted toward a more patient-centric, consumeristic model, marked by an emphasis on choice and a proliferation of typical consumer-facing information (e.g., price and quality data). However, while the... View Details
Keywords: Medical Decision-making; Choice; Health Care and Treatment; Quality; Price; Consumer Behavior; Decision Making
Barasz, Kate, and Peter A. Ubel. "Unhealthy Consumerism: The Challenge of Trading Off Price and Quality in Healthcare." Behavioural Public Policy 2, no. 1 (May 2018): 41–55.
- August 2007 (Revised November 2008)
- Case
Biocon: Launching a New Cancer Drug in India
By: Sunil Gupta and Das Narayandas
Kiran Majumdar-Shaw, the CEO of Biocon has to make product launch timing, pricing, channel, and communications mix decisions relating to the launch of BioMAb, a new cancer drug in India. View Details
Keywords: Price; Health Care and Treatment; Marketing Strategy; Product Launch; Planning; Biotechnology Industry; Pharmaceutical Industry; India
Gupta, Sunil, and Das Narayandas. "Biocon: Launching a New Cancer Drug in India." Harvard Business School Case 508-026, August 2007. (Revised November 2008.)
- January 2006 (Revised May 2007)
- Case
Endo Pharmaceuticals (A): From LBO to...?
By: Richard G. Hamermesh and Brian DeLacey
Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details
Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (A): From LBO to...?" Harvard Business School Case 806-064, January 2006. (Revised May 2007.)
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- June 9, 2023
- Article
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." New England Journal of Medicine 386, no. 23 (June 9, 2023): 2157–2159.
- April 2018 (Revised September 2018)
- Case
Impact Investing for Cancer
By: Richard G. Hamermesh and Matthew G. Preble
It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer... View Details
Keywords: Impact Investing; Investment; Health Disorders; Philanthropy and Charitable Giving; Decision Choices and Conditions
Hamermesh, Richard G., and Matthew G. Preble. "Impact Investing for Cancer." Harvard Business School Case 818-068, April 2018. (Revised September 2018.)